Scientific Advisory Board | Nurix
Our goal is to empower the body to fight disease using small molecule drugs to activate or inhibit the natural process of protein degradation. We are committed to the highest level of scientific inquiry and integrity. Nurix is committed to bringing novel, first-in-class therapies to patients without adequate treatment options. Nurix was founded by a team of internationally renowned experts in the fields of E3 ubiquitin ligase regulation and structure. Since its incorporation, Nurix has built a seasoned team of leaders with wide-ranging backgrounds in small molecule drug development and cancer therapy. Phelps has more than 10 years of experience in small molecule discovery, with a focus on DNA encoded library technology. Benson has over 22 years of experience in drug development across numerous indications and has worked on five drugs that have received FDA approval. Demirhan brings over 17 years of experience in drug pharmaceuticals and biotechnology, championing data-driven drug development ideology and implementation.
This company is:
Verified
Targeted Protein Degradation | Nurix
Targeted Protein Degradation (TPD): A New Generation of Therapeutics Drugging the Undruggable E3 ligases catalyze the transfer of ubiquitin onto a target protein. The presence of the ubiquitin tag destines the protein for destruction by the proteasome. Targeted Protein Degraders are small molecules that simultaneously bind an E3 ligase and a target protein to facilitate […]
Verified
Targeted Protein Modulation | Nurix
Targeted Protein Modulation (TPM): Engaging ligases to treat disease Nurix is leading the field in Targeted Protein Modulation Nurix has built a drug discovery engine focused on the modulation of E3 ligases to modulate protein levels directly and specifically in cells. Targeted Protein Modulation comprises two key modalities: Targeted Protein Degradation, which aims to harness […]
Verified
DELigase | Nurix
Combining the Power of DEL With Industry-Leading E3 Ligase Expertise DELigase Platform Our DELigase platform, which enables our robust drug discovery pipeline, relies on two underlying features – our collection of E3 ligases and our DNA-encoded libraries of small molecules. Our platform is highly differentiated and allows us to identify small molecules that can either […]
View all products
Keywords
Industries
Application of DNA-Encoded Libraries to Discover Small Molecules for E3 Ligase Modulation | Nurix
Application of DNA-Encoded Libraries to Discover Small Molecules for E3 Ligase Modulation
Where is Nurix Therapeutics located?
The company Nurix Therapeutics is located in San Francisco, California, United States. It's worth noting that the company may has more corporate locations
How many employees does Nurix Therapeutics approximately have?
As of the latest available information Nurix Therapeutics has around 101-250 employees worldwide.
When was Nurix Therapeutics founded?
Nurix Therapeutics was founded in 2012
In which industries does Nurix Therapeutics mainly work?
The company Nurix Therapeutics has it's main focus in the industries of Science and Engineering, Health Care, Biotechnology, Professional Services
What is the current company status of Nurix Therapeutics?
Based on the founding year and the amount of employees the company Nurix Therapeutics seems to be a Medium-Sized Company at the current state. Note that over time that status can change
Nerx Biosciences, Inc.
United States
1-10 Employees
2010
Kojin Therapeutics
United States
11-50 Employees
2020
BUGWORKS Research
India
11-50 Employees
2014
NexusPharma
United States
11-50 Employees
2004
Nexcyon Pharmaceuticals
United States
11-50 Employees
2008
Midatech Pharma
11-50 Employees
2000
Vivoryon Therapeutics
Germany
101-250 Employees
1997
N1 Life
United States
1-10 Employees
2019
Topics which have been searched by others and may be interesting for you:
